About Synaptotagmin-1
Synaptotagmin-1 (SYT1) is a protein
from Homo sapiens identified by UniProt accession
P21579, 422 residues long.
MolForge cross-references it against 0 known binders and
183 disease associations.
Target properties
| Protein name | Synaptotagmin-1 |
| UniProt accession | P21579 |
| Gene | SYT1 |
| Organism | Homo sapiens |
| Length | 422 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (183)
Diseases linked to this target (Open Targets).
- infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome · score 0.73
- Intellectual disability · score 0.55
- botulism · score 0.55
- genetic disorder · score 0.45
- intelligence · score 0.38
- systolic blood pressure · score 0.38
- self reported educational attainment · score 0.38
- cognitive function measurement · score 0.38
- grip strength measurement · score 0.36
- syndromic intellectual disability · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P21579-F1 | alphafold | PREDICTED | 81.81 | — |
Amino-acid sequence (422 residues)
MVSESHHEAL AAPPVTTVAT VLPSNATEPA SPGEGKEDAF SKLKEKFMNE LHKIPLPPWA LIAIAIVAVL LVLTCCFCIC KKCLFKKKNK KKGKEKGGKN AINMKDVKDL GKTMKDQALK DDDAETGLTD GEEKEEPKEE EKLGKLQYSL DYDFQNNQLL VGIIQAAELP ALDMGGTSDP YVKVFLLPDK KKKFETKVHR KTLNPVFNEQ FTFKVPYSEL GGKTLVMAVY DFDRFSKHDI IGEFKVPMNT VDFGHVTEEW RDLQSAEKEE QEKLGDICFS LRYVPTAGKL TVVILEAKNL KKMDVGGLSD PYVKIHLMQN GKRLKKKKTT IKKNTLNPYY NESFSFEVPF EQIQKVQVVV TVLDYDKIGK NDAIGKVFVG YNSTGAELRH WSDMLANPRR PIAQWHTLQV EEEVDAMLAV KK
Explore Synaptotagmin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets